Abstract:Irritable bowel syndrome (IBS) is an extremely common and often very debilitating chronic functional gastrointestinal disorder. Despite its prevalence, significant associated healthcare costs, and quality-of-life issues for affected individuals, our understanding of its etiology remained limited. However, it is now evident that microbial factors play key roles in IBS pathophysiology. Acute gastroenteritis following exposure to pathogens can precipitate the development of IBS, and studies have demonstrated changes in the gut microbiome in IBS patients. These changes may explain some of the symptoms of IBS, including visceral hypersensitivity, as gut microbes exert effects on the host immune system and gut barrier function, as well as the brain–gut axis. Microbial differences also appear to underlie the two main functional categories of IBS: diarrhea-predominant IBS (IBS-D) is associated with small intestinal bacterial overgrowth, which can be diagnosed by a positive hydrogen breath test, and constipation-predominant IBS (IBS-C) is associated with increased levels of methanogenic archaea, which can be diagnosed by a positive methane breath test. Mechanistically, the pathogens that cause gastroenteritis and trigger subsequent IBS development produce a common toxin, cytolethal distending toxin B (CdtB), and antibodies raised against CdtB cross-react with the cytoskeletal protein vinculin and impair gut motility, facilitating bacterial overgrowth. In contrast, methane gas slows intestinal contractility, which may facilitate the development of constipation. While antibiotics and dietary manipulations have been used to relieve IBS symptoms, with varying success, elucidating the specific mechanisms by which gut microbes exert their effects on the host may allow the development of targeted treatments that may successfully treat the underlying causes of IBS.

Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome

Intestinal Crosstalk Between Microbiota and Serotonin and Its Impact on Gut Motility

Involvement Of Corticotropon-Relesing Factor And Receptors In Immune Cells In Irritable Bowel Syndrome

Potential neuro-immune therapeutic targets in irritable bowel syndrome

Targeting the gut-microbiota-brain axis in irritable bowel disease to improve cognitive function - recent knowledge and emerging therapeutic opportunities

Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome

Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management

Intestinal Crosstalk between Bile Acids and Microbiota in irritable bowel syndrome

Aggregation and Self-Assembly of Hydrophobins from Trichoderma Reesei: Low-Resolution Structural Models

Gut microbiota and intestinal immunity—A crosstalk in irritable bowel syndrome

Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review

The neurobiology of irritable bowel syndrome

Impact of Enteric Nervous Cells on Irritable Bowel Syndrome: Potential Treatment Options

Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships

Microbiome and Its Role in Irritable Bowel Syndrome

The Role of Short Chain Fatty Acids in Irritable Bowel Syndrome

The function of the gut microbiota–bile acid–TGR5 axis in diarrhea-predominant irritable bowel syndrome

Gut Microbiota and Irritable Bowel Syndrome: Status and Prospect

Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome

The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy

Gut microbiota modulates neurotransmitter and gut-brain signaling